ada guidelines glp 1 for Diabetes 2026 #ada #diabetes @dr_samia_asim The Benefits of Incretin Mimetics

Novo Nordisk is the market leader: Ozempic (weekly injection for type 2 diabetes) Wegovy (higher-dose weekly injection for obesity) Rybelsus ( Oral tablets for diabetes Oral tablets for weight management is in phase 3 trials) Eli Lilly is the other major player: Mounjaro (weekly injection for type 2 diabetes) Zepbound (higherdose weekly injection for obesity) This duopoly meant that both stocks had an incredible run-up from 2020 to 2024

Cost benefit analysis Currently this medicine-induced freedom is only available to the ones who can afford it (the treatment costs approximately 100/week so national healthcare systems do not want to pay) or, like me, are willing to prioritize not to die prematurely, for instance by letting go of the car or having fewer long haul vacations

December 14, 2023

Mao D, Cao H, Shi M, Wang CC, Kwong J, Li JJX, et al